Will TB006 Be to Brain Health What GLP-1s Are to Weight Loss?

How will you ride the wave?

Over the last few years, we’ve witnessed one of the most dramatic shifts in modern health behavior and business strategy: companies that once championed natural weight loss through diet and behavior change—think Noom, Weight Watchers, and others—have pivoted almost entirely to become GLP-1 support companies. That’s right—platforms once built around coaching, psychology, calorie counting, and lifestyle tracking are now wrapping themselves around pharmaceutical protocols.

Why? Because GLP-1s work, at least in terms of moving the needle on weight. For the first time in recent history, the average weight of Americans is going down—a reversal of decades-long trends. Whether you love them or hate them, GLP-1s are big business, and their impact has already reshaped the landscape of chronic disease “management”.

So here’s the question: What would you have done differently five years ago if you had known GLP-1s were going to be this big? How would you have structured your practice to support those patients? We now see innovative functional medicine and longevity clinics creating GLP-1 optimization programs—not to replace the medication, but to reduce its risks, enhance its benefits, and transition patients toward sustainable health outcomes.

Now, it appears that a similar pharmaceutical moment could be coming to brain health—and it's called TB006.

---

Introducing TB006: The GLP-1 of the Brain?

TB006 is currently in clinical trials, and while it's not available to the public yet, early reports are generating serious buzz. Developed by Shanghai-based biotech Shanghai Green Valley Pharmaceuticals, TB006 is designed to target neuroinflammation, a known driver of Alzheimer’s disease, cognitive decline, and even mental health conditions like anxiety and depression.

While most Alzheimer’s drugs over the last two decades have focused on reducing beta-amyloid plaques—a hypothesis now riddled with controversy and failure—TB006 is part of a new generation of therapies aimed at resolving inflammation at the source. It works by targeting and neutralizing Galectin-3, a protein involved in neuroinflammation and the formation of toxic protein aggregates.

If successful, TB006 could be to brain health what GLP-1s have been to weight loss:

• A high-cost, high-impact pharmaceutical

• That delivers visible results

• And quickly becomes standard of care for millions of patients

And just like GLP-1s, it won’t be enough on its own.

---

Inflammation Is the Common Thread

Whether we’re talking about cognitive decline, Alzheimer’s, or anxiety and depression, neuroinflammation is the common denominator. Brain inflammation has been implicated in the breakdown of memory, executive function, emotional regulation, and even the blood-brain barrier. And it’s not just affecting older populations. We’re seeing a rise in cognitive and emotional dysfunction across all age groups—a trend that’s deeply connected to the modern lifestyle and environmental toxicity.

So, when TB006 becomes widely available, expect it to catch fire—especially with:

• Boomers, who have the means to pay

• Caregivers, desperate for hope

• Clinics, eager to adopt the next new thing

But also expect it to come with the same challenges as GLP-1s:

• High cost

• Risk of over-reliance

• Lack of long-term strategy

---

How Should You Prepare Your Practice for TB006?

Just like GLP-1s revealed the need for medication optimization programs, TB006 will highlight the need for brain health optimization—a model of care that integrates the best of functional medicine, precision diagnostics, and lifestyle modification.

That’s exactly what we’ve built at TruNeura.

Our platform isn’t just built to track data—it’s built to deliver brain health outcomes in both short and long term. Rooted in the proven clinical model of Dr. Kristine Burke, one of the leading physicians in cognitive decline reversal, TruNeura gives you a turnkey framework to:

• Score and organize 450+ biomarkers into root-cause categories

• Track cognitive function, labs, and wearables in one integrated system

• Prescribe personalized lifestyle interventions across eight lifestyle pillars

• Deliver care in a repeatable, scalable model that supports patient participation and accountability

With TB006 on the horizon, clinics will need a structured way to:

• Evaluate whether a patient is a good candidate

• Track response to therapy

• Address underlying drivers of inflammation and degeneration

• Transition patients to a long-term care strategy that builds a resilient brain

---

TruNeura: Powering the Brain Health Clinics of the Future

We’ve already helped clinics structure multi-tier brain health memberships that address the three biggest brain health categories:

1. Cognitive decline & early Alzheimer’s

2. Root-cause mental health

3. Perimenopause brain (and hormone-brain connection)

And we do it with a model that scales—one provider, one coach, and one year to a $1M brain health membership program. That’s not theory. That’s a reasonable path forward with execution and focus.

The future of medicine is brain-focused, and the arrival of TB006 is only going to accelerate that shift. If you want your clinic to be at the forefront—not just reacting to trends but leading the conversation—now is the time to prepare.

---

The Bottom Line

The GLP-1 moment changed the game in metabolic care. TB006 could do the same for cognitive care.

• Will it work? Possibly.

• Will it be expensive? Almost certainly.

• Will patients demand it? Without a doubt.

But no matter how powerful TB006 turns out to be, it won’t solve everything. The only way to create lasting transformation in brain health is to address the root causes, track behavior, and support the patient between visits.

That’s what TruNeura was built to do.

And if you want to build the brain health clinic of the future, we’re ready to help.

---